Insightful Analysis on Economics, Markets & Global Affairs

Atlas Renewable Energy has halted $1 billion in Brazil projects because the national grid keeps rejecting the solar power it already generates.

Fulcrum Therapeutics scrapped its sickle-cell drug after the FDA said its entire target protein complex carries cancer risk, leaving a disease with few good options even worse off.

Rising energy costs, currency swings, and cautious consumers are squeezing Philip Morris, and its flagship nicotine pouch is getting a cheaper sibling to fight back.

Tom Mueller, SpaceX's founding engineer, has raised $500 million at a $4.26 billion valuation to build the "last mile" of space logistics.

An activist investor says Voya Financial is undervalued and underled, and is pushing the board to explore a sale of the $7.4 billion insurance giant.

SpaceX reserved 5% of its IPO for hand-picked insiders with no lock-up, while the rest of the market waits months to trade.

617 workers plan to walk off offshore platforms June 5 if wage talks fail, threatening output that heats homes and powers factories across Europe.

FedEx Freight's first day as an independent company ended with shares down nearly 3%, as analysts flagged execution risks and a messy transition ahead.